About Niv Papo
Angiogenesis is the process of new blood vessel development, a hallmark of cancer and Prostate Specific Membrane Antigen (PSMA) is a protein expressed on the surface of prostate tumor cells.
Dr. Papo intends to produce engineered proteins that will simultaneously bind to PSMA on prostate cancer cells and inhibit angiogenesis.
This engineered protein inhibitor should be a drug candidate for the treatment advanced, metastatic prostate cancer.
What this means for patients: This is a novel therapeutic candidate for the treatment of advanced, metastatic prostate cancer.
2013 Joseph Neubauer-PCF Young Investigator
Niv Papo, PhD
Ben-Gurion University of the Negev (Israel)
Eyal Mishani, PhD
Developing novel dual-specific proteins that target multiple receptors for applications in prostate cancer imaging and therapy